BridgeBio Pharma, Inc. Equity Securities, FV-NI, Realized Gain (Loss)
BridgeBio Pharma, Inc. (BBIO) reported Equity Securities, FV-NI, Realized Gain (Loss) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2026-02-24
- BridgeBio Pharma, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Pharma, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2024-12-31 was -$36.00K.
- BridgeBio Pharma, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Pharma, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Pharma, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BridgeBio Pharma, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2024 was $8.10M, a 6.90% decline from fiscal 2023.
- BridgeBio Pharma, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2023 was $8.70M, a 133.18% increase from fiscal 2022.
- BridgeBio Pharma, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2022 was $3.73M, a 69.13% increase from fiscal 2021.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 3 month | Equity Securities, FV-NI, Realized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Realized Gain (Loss) 6 month | Equity Securities, FV-NI, Realized Gain (Loss) 9 month | Equity Securities, FV-NI, Realized Gain (Loss) 12 month | Equity Securities, FV-NI, Realized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 | |||||
| 2025-03-31 | $0.00 10-Q · filed 2025-04-29 | -$36.00K derived: sum of 2 quarters · filed 2026-02-24 | -$36.00K derived: sum of 3 quarters · filed 2026-02-24 | -$36.00K derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-12-31 | -$36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$36.00K derived: sum of 2 quarters · filed 2026-02-24 | -$36.00K derived: sum of 3 quarters · filed 2026-02-24 | $8.10M 10-K · filed 2026-02-24 | $8.14M 10-K · filed 2025-02-20 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $8.14M 10-Q · filed 2024-11-12 | $7.75M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 | $8.14M 10-Q · filed 2024-08-01 | $7.75M derived: sum of 3 quarters · filed 2026-02-24 | $8.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $8.10M 10-Q · filed 2025-04-29 | $8.14M 10-Q · filed 2024-05-02 | $7.75M derived: sum of 2 quarters · filed 2026-02-24 | $8.00M derived: sum of 3 quarters · filed 2026-02-24 | $9.64M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | -$349.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$96.00K derived: sum of 2 quarters · filed 2026-02-24 | $1.54M derived: sum of 3 quarters · filed 2026-02-24 | $8.70M 10-K · filed 2026-02-24 | $8.67M 10-K · filed 2024-02-22 | |
| 2023-09-30 | $253.00K 10-Q · filed 2024-11-12 | $1.89M derived: sum of 2 quarters · filed 2024-11-12 | $9.05M 10-Q · filed 2024-11-12 | $12.42M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2023-06-30 | $1.64M 10-Q · filed 2024-08-01 | $8.80M 10-Q · filed 2024-08-01 | $12.17M derived: sum of 3 quarters · filed 2025-02-20 | $13.91M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2023-03-31 | $7.16M 10-Q · filed 2024-05-02 | $10.53M derived: sum of 2 quarters · filed 2025-02-20 | $12.27M derived: sum of 3 quarters · filed 2025-02-20 | $12.13M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2022-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $5.12M derived: sum of 2 quarters · filed 2025-02-20 | $4.97M derived: sum of 3 quarters · filed 2025-02-20 | $3.73M 10-K · filed 2025-02-20 | ||
| 2022-09-30 | $1.75M 10-Q · filed 2023-11-02 | $1.60M derived: sum of 2 quarters · filed 2023-11-02 | $360.00K 10-Q · filed 2023-11-02 | $1.90M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-06-30 | -$141.00K 10-Q · filed 2023-08-03 | -$1.39M 10-Q · filed 2023-08-03 | $157.00K derived: sum of 3 quarters · filed 2024-02-22 | $808.00K derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-03-31 | -$1.24M 10-Q · filed 2023-05-04 | $298.00K derived: sum of 2 quarters · filed 2024-02-22 | $949.00K derived: sum of 3 quarters · filed 2024-02-22 | |||
| 2021-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.19M derived: sum of 2 quarters · filed 2024-02-22 | $2.21M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $651.00K 10-Q · filed 2022-11-03 | $664.00K 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |